Lagares A.D. et al. published similar data evaluating the potential clinical use of MIA and S100B as tumor markers in the advanced stages, and it was shown that 75.7% of patients with distant metastases and 63.2% in stage IIIC had higher levels for either S100B or MIA soluble proteins [50,51]. Here, S100B is linked to neoplasm.